Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2009 | Stemgent | Series B | 14M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 9/2002 | Glaukos | Series A | 10M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2014 | PowerVision | Series D | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 1/1996 | Corixa | Venture Round | - |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 1/2005 | PowerVision | Series A | 4.4M |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 3/2007 | Stromedix | Series A | 1M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 1/1993 | VIVUS | Venture Round | - |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 1/2006 | Xoft | Series C | 0 |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 10/2005 | EBR Systems | Series B | 21M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 1/1996 | ViroPharma | Funding Round | - |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 5/2007 | CVRx | Series D | 65M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 7/2011 | PowerVision | Series C | 24M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 12/2007 | Barosense | Series C | 11.2M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2017 | Mavupharma | Series A | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2020 | Inipharm | Series A | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 3/2019 | Scout Bio | Series B | 20M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 6/2008 | EBR Systems | Series C | 35M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 8/2008 | Calibra Medical | Series B | 35M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 11/2009 | Calypso Medical | Series E | 50M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 6/2005 | Cierra | Funding Round | 21M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 10/2003 | Cotherix | Series C | 55M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 8/2009 | Barosense | Series D | 27M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 7/2013 | Alcresta | Series B | 10M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 6/2003 | Xoft | Series B | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 4/2008 | Stromedix | Series B | 25M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 3/2006 | PowerVision | Series A | 2M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 2/2007 | Pivot Medical | Series A | 2M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 12/2003 | FlowCardia | Series B | 12M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
